Last reviewed · How we verify
Remaxa, enteric-coated tablets — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Remaxa, enteric-coated tablets (Remaxa, enteric-coated tablets) — POLYSAN Scientific & Technological Pharmaceutical Company.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Remaxa, enteric-coated tablets TARGET | Remaxa, enteric-coated tablets | POLYSAN Scientific & Technological Pharmaceutical Company | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Remaxa, enteric-coated tablets CI watch — RSS
- Remaxa, enteric-coated tablets CI watch — Atom
- Remaxa, enteric-coated tablets CI watch — JSON
- Remaxa, enteric-coated tablets alone — RSS
Cite this brief
Drug Landscape (2026). Remaxa, enteric-coated tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/remaxa-enteric-coated-tablets. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing